NeoImmuneTech, Inc.   Report issue

For profit Phase 1 Phase 2
Founded: Seongnam Korea, Republic of (2014)

Organization Overview

First Clinical Trial
2019
NCT03901573
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

NeoImmuneTech | NeoImmune Tech | NeoImmuneTech, Inc.